




Passion. Innovation. Life.

Trusted **CIDMO** partner in
your journey from lab to leash

www.enzene.com

Delivering significant cost advantage at higher productivity, quality and sustainability through EnzeneX™



Fully-connected continuous manufacturing™ (FCCM™) offers an innovative and progressive alternative to the conventional fed-batch and semi-continuous processes, particularly in the production of complex biologics. It entails seamless and uninterrupted processing from initial cell culture to the final drug substance. This patented technique optimizes quality, efficiency, and flexibility in delivery.

Enzene is changing the paradigm with EnzeneX™

With a vision to positively impact the global healthcare landscape by developing cost-effective therapeutics, Enzene has been at the forefront of disruptive innovation in the biotech space since 2016. EnzeneX™ utilizes Enzene's patented and commercially validated fully-connected continuous manufacturing™ technology - the next step in revolutionizing the industry. And now, Enzene has expanded its vision to the U.S. aiming to create access equity by providing cost-effective, high quality, sustainable manufacturing to animal health, small and mid-size pharma companies.

Launched our USDA designed facility in 2025

Enzene's new U.S. facility is manufacturing its first animal health product, marking a significant milestone in the company's expansion efforts. With this inaugural product, Enzene is poised to make a meaningful impact on the animal health industry.

Advantages of EnzeneX™



Productivity

Up to **10x** higher than traditional fed batch

Cost of Goods

Up to **50%** reduction in COGS



Superior Quality

Minimized product contact with cell culture fluid reduces aggregation and degradation even for less-stable and difficult-to-express proteins




Flexibility

Clinical phase GMP supply in **30-50L** scale & modular design with variable bioreactor capacity accelerates development with scale-on / scale-out approaches



Sustainability

Up to **50%** decrease in carbon emission



Accelerated pace

~**10** months from gene to phase 1

Facility Footprint

Up to **70%** reduction in footprint



Case study- Converting fed-batch to fully-connected continuous manufacturing™ (FCCM™) for an IgG1

Molecule under study

Felized monoclonal antibody

Problem statement

The client wanted to evaluate the feasibility of converting their fed-batch process to a perfusion run using our FCCM™ platform.



Enzene's approach

At Enzene, we performed both fed-batch and perfusion (using FCCM™) runs with the same clone and compared their productivity and quality side-by-side.

Outcome

As indicated from the data, Enzene's FCCM™ technology outperformed fed batch in terms of quantity and quality.

A 5-fold increase was observed in cumulative productivity.



*Our microbial and mammalian DS plants as well as our sterile fill & finish plant have received EU-GMP certification



Contact us today - bd@enzene.com | www.enzene.com